This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.
Primary Objective:
- To generate a repository of participant-derived tumor models* and specimens** -annotated with demographic, clinical, and pathologic data - from adults with solid tumor malignancies with germline or somatic tumor-associated mutations and/or a personal or family history of cancer.
Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs).
- Specimens may include tissue, ascites and pleural fluid, and blood.
Exploratory Objectives
- To correlate in vivo drug sensitivity of participant-derived models with patient clinical response.
- To conduct blood-based assessment of tumor-associated biomarkers (DNA/RNA/protein, etc.).
- To describe tumor and blood-based biomarkers that are predictive of clinical response.
- To correlate changes in tumor and blood-based biomarker expression with clinical outcomes over time.
- To perform genomic and transcriptomic profiling of banked specimens and correlate findings with clinical outcomes, prognostic markers, and biomarkers.
- Unspecified cancer-centric research in the Munster Lab and other future unspecified research.
OUTLINE:
Participants will have biospecimens collected at non-study, routine procedures or visits to be stored at UCSF. Specimens will be processed and banked as per standard operating procedure. Participants will be followed through medical record chart review for a period of 10 years after signing informed consent, and be contacted every 3 months (± 2 months) for the first year and every 6 months (± 3 months) thereafter to allow updates to health status.